H2A.Z2 is a histone variant that replaces conventional H2A in nucleosomes to regulate chr7 accessibility and gene expression. As a structural component of chr7, H2A.Z2 facilitates transcription factor recruitment to gene promoters and enhancers, thereby controlling DNA accessibility for transcriptional machinery 1. In normal physiology, H2A.Z2 expression is dynamically regulated during keratinocyte differentiation, with SRCAP-dependent deposition essential for epidermal progenitor maintenance and nuclear integrity 2. H2A.Z2 has emerged as an oncogenic factor in multiple cancer types. In cervical cancer, H2A.Z2 is overexpressed and enriched at promoters and enhancers of proliferation-associated genes, with transcription factors AP2α and ELK1 driving its upregulation 3. In glioblastoma, H2A.Z2 overexpression sustains chr7 accessibility at cell cycle genes and is co-activated by E2F1 and STAT3 transcriptional synergy 1. Clinically, E2F/STAT3 inhibitor combinations effectively suppress glioblastoma tumorigenicity in xenograft models, suggesting H2A.Z2 as a therapeutic target 1. The dual role of H2A.Z2—essential for normal progenitor function yet frequently dysregulated in cancer—indicates context-dependent contributions to both cellular homeostasis and malignant transformation.